Q-omics provides the consensus-scored CXCL13 profile across patient tissues and cancer cell-line models. CXCL13 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CXCL13 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CXCL13 RNA expression shows 16,002 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where CXCL13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXCL13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXCL13 survival associations across molecular data types. CXCL13 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXCL13 RNA expression–survival associations across cancer types. High CXCL13 expression shows unfavorable associations in UVM and KIRP, but favorable associations in HNSC, SKCM, OV and STAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CXCL13 RNA expression.
This table summarizes CXCL13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CXCL13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXCL13 shows lower tumor expression in COAD and higher tumor expression in HNSC, KIRC, LUAD, STAD and LUSC. The HNSC box plot shows higher CXCL13 RNA expression in tumor versus normal tissue (log2 FC = +2.364, t-test p < 0.001).
This table shows molecular features associated with CXCL13 in patient tissues and cancer cell lines. In patient samples, CXCL13 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CXCL13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_NSCLC_LUAD.
